Israeli Anti-Obesity Drug Shown To Have Limited Impact On Habits
This article was originally published in PharmAsia News
Executive SummaryIsrael's anti-obestity drug, Histalean, has been shown in an early clinical trial to stem weight gains in participating patients, but not to significant levels
You may also be interested in...
Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.
Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.